Clinical trials: Malaria, Falciparum
Malaria,Falciparum, Malaria in Pregnancy
Plasmodium Falciparum Genomic Intelligence in Mozambique
Mozambique is among the ten countries with the highest burden of malaria worldwide, with an estimated 9.3 million cases in 2018, and constitutes a core target for the World Health Organization (WHO) and the Roll Back Malaria…
- Conditions
- Malaria,Falciparum, Malaria in Pregnancy, Malaria
- Trial name
- GenMoz (NCT05306067)
- Testing
- LDH-based malaria rapid diagnostic test, Malaria rapid diagnostic test
- Where
- Mozambique
- Volunteers
- 21,848 people, healthy volunteers welcome
- Sponsor
- Centro de Investigacao em Saude de Manhica
Malaria
Parasite Clearance and Protection From Infection (PCPI) in Zambia
The Zambia PCPI study will measure the effect of the parasite genotypes associated with SP resistance on parasite clearance and protection from infection when exposed to SP.
- Trial name
- NCT06166498
- Testing
- SP (Macleods Pharmaceuticals Ltd), AS (Guilin Pharmaceuticals)
- Where
- Zambia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria,Falciparum
Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemoprevention
In areas of the Sahel sub-region of Africa with intense seasonal malaria transmission, seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SP+AQ) has become the standard-of-care for the…
- Trial name
- DRUMARS (NCT04969185)
- Where
- 2 sites in Burkina Faso
- Volunteers
- 310 people
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria
Pentoxifylline in Children With Malaria
The primary objectives of this study is to identify a safe, tolerable dose of pentoxifylline in children with cerebral malaria and to establish an acceptable pentoxifylline dosage regimen for use in multi center Phase II and…
- Trial name
- NCT00133393
- Testing
- Pentoxifylline
- Where
- Kenya
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Weight Loss, Weight Gain
Effect of Ready to Use Therapeutic Food (RUTF) Supplement After an Episode of Malaria Falciparum on Weight
The primary objective of this study is to determine to what extent provision with RUTF will promote catch up growth in children following an acute uncomplicated episode of P. falciparum malaria.
- Conditions
- Weight Loss, Weight Gain, Convalescence, Malaria
- Trial name
- NCT00819858
- Testing
- RUTF (Plumpynut®)
- Where
- Republic of the Congo
- Volunteers
- 180 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Severe Malaria
Monitoring of Molecular Markers of Artemisinin Resistance Through Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda
Currently, 16 African countries include the use of pre-referral rectal artesunate (RAS) in their treatment policies. However, guidelines for RAS use vary widely across countries and inappropriate use of RAS as a monotherapy and…
- Trial name
- Caramal DRM (NCT04037332)
- Testing
- Blood sample (combined with malaria RDT) followed by gentoyping analysis
- Where
- 7 sites in Democratic Republic of the Congo, Nigeria and 1 more
- Volunteers
- 916 people
- Sponsor
- Swiss Tropical & Public Health Institute
Malaria
Intermittent Preventive Treatment in Infant in Mali
Studies have shown that Intermittent preventive treatment in infants (IPTi) with Sulfadoxine-pyrimethamine (SP)reduced the incidence of clinical malaria and anemia without modifying infants' serological response to EPI vaccines.
- Trial name
- NCT00766662
- Testing
- Sulfadoxine pyrimethamine
- Where
- Mali
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Bamako
Malaria, Falciparum
Mass-Drug Administration to Reduce Malaria Transmission
In the 1950s, the WHO included mass drug administration (MDA) with antimalarial drugs as a tool for malaria control in 'exceptional conditions when conventional control strategies have failed'.
- Trial name
- MDATRANS (NCT00509015)
- Testing
- Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Artesunate (day 1,2,3: 4 mg/kg), Primaquine-base (day 3: 0.75 mg/kg)
- Where
- Tanzania
- Volunteers
- 6,000 people
- Sponsor
- Radboud University Medical Center
Plasmodium Falciparum Malaria
Hyperphenylalaninemia in Cerebral Malaria
The purpose of this study is to see if children, who develop coma from malaria, are not making enough of a vitamin-like chemical, tetrahydrobiopterin (BH4), which is required for the brain to function normally.
- Trial name
- NCT00338520
- Where
- Tanzania
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- University of Utah
Malaria, Falciparum
Study of the Impact of Intermittent Preventive Treatment in Schools on Malaria, Anaemia and Education.
This study seeks to establish whether intermittent preventive treatment (IPT) can reduce malaria among school-going children and its consequent impact on school performance.
- Trial name
- NCT00142246
- Testing
- Intermittent preventive treatment (SP and amodiaquine)
- Where
- Kenya
- Volunteers
- 6,758 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Uncomplicated P. Falciparum Malaria
SPK Study in Afghanistan
In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium falciparum resistance to chloroquine. In 2003 the high failure rate of chloroquine against falciparum malaria led the national malaria…
- Trial name
- NCT01707199
- Testing
- Artesunate + Sulphadoxine-pyrimethamine
- Where
- Afghanistan
- Volunteers
- 83 people
- Sponsor
- University of Oxford
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07235033)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 3 sites in Côte d’Ivoire, Gabon and 1 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Uncomplicated Malaria
Treatment of Uncomplicated Malaria in Benin
Malaria is a life-threatening disease especially in small children. A high degree of Plasmodium falciparum resistance to chloroquine has already spread to South-Benin where this study is taking place.
- Trial name
- NCT00460369
- Testing
- sulfadoxine-pyrimethamine, artemether-lumefantrine, amodiaquine-artesunate coformulation
- Where
- Benin
- Volunteers
- 240 people
- Sponsor
- Institut de Recherche pour le Developpement
Plasmodium Infections
Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan
In areas of seasonal malaria transmission, treatment of carriers of malaria parasites, whose parasitaemia persists at very low levels throughout the dry season, could be a useful strategy for malaria control in areas with a short…
- Trial name
- NCT00330902
- Testing
- sulfadoxine-pyrimethamine (SP) plus artesunate (AS), primaquine (PQ) plus SP+AS
- Where
- Sudan
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Acute Uncomplicated Plasmodium Falciparum Malaria
Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
This study was designed to determine the most effective and tolerable dose at the shortest dosing regimen of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in…
- Trial name
- NCT03167242
- Testing
- KAF156, Coartem, Lumefantrine Solid Dispersion Formulation
- Where
- 11 sites in Burkina Faso, Gabon and 7 more
- Volunteers
- 524 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger
Study treatments: Artemether-lumefantrine Artesunate-amodiaquine Dihydroartemisinin-piperaquine Location: Maradi, Niger Principal Objective: To measure the clinical and parasitological efficacy of the three artemisinin…
- Trial name
- NCT01755559
- Testing
- Artesunate-amodiaquine, Dihydroartemisinin-piperaquine, Artemether-lumefantrine
- Where
- Niger
- Volunteers
- 663 people
- Sponsor
- Epicentre
Plasmodium Falciparum, Malaria
Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia
To assess the efficacy of both first-line antimalarial medications used for the treatment of uncomplicated Plasmodium falciparum malaria infections in two geographic regions in Liberia.
- Conditions
- Plasmodium Falciparum, Malaria, Uncomplicated Malaria
- Trial name
- NCT06300970
- Testing
- Amodiaquine-artesunate (ASAQ), Artemether+Lumefantrine (AL)
- Where
- 2 sites in Liberia
- Volunteers
- 352 people
- Sponsor
- Centers for Disease Control and Prevention
Uncomplicated P. Falciparum Malaria in Children
Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso
Several countries in Africa have changed their first-line treatment for uncomplicated malaria to an ACT. Burkina Faso has changed its policy to Artemether-Lumefantrine (AL) and Artesunate-Amodiaquine (AQ+AS).
- Trial name
- ACTE (NCT01017770)
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- 4 sites in Burkina Faso
- Volunteers
- 340 people
- Sponsor
- Centre Muraz
Malaria
Artemisinin Resistance in Bangladesh
A randomized, controlled clinical trial conducted in Southeastern Bangladesh using artesunate monotherapy to determine the baseline sensitivity of P. falciparum to artemisinins.
- Trial name
- NCT00639873
- Testing
- Artesunate, quinine-doxycycline
- Where
- Bangladesh
- Volunteers
- 126 people
- Sponsor
- Medical University of Vienna
Malaria,Falciparum
Cohort Event Monitoring Study of Pyramax®
The study is to be performed in public health facilities in Central and West Africa where Pyramax will be used as treatment of uncomplicated malaria episodes, including repeat episodes.
- Trial name
- NCT03201770
- Testing
- pyronaridine artesunate
- Where
- 5 sites in Cameroon, Côte d’Ivoire and 3 more
- Volunteers
- 8,572 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.